Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis.

Karen J Neelis, Django M Kip, Frank M Speetjens, Yvette M van der Linden

Radiation oncology (London, England) 2022 Apr 20

filter terms:

To gain insight into the treatment outcomes for anal cancer a retrospective analysis was performed with a special emphasis on trends in outcome and toxicities over time and on treatment of elderly patients. Medical records of 98 consecutive patients with squamous cell carcinoma of the anus of all stages treated with curative intent between 01-01-2009 and 31-12-2018 were analyzed with follow up until 31-12-2020. Standard tumor and pathological lymph node dose were 59.4 Gy (median 59.4 Gy, range 59.4-70 Gy) or 60 Gy (no deviation from intended dose), elective nodal regions were treated with 45 Gy (no deviations). Radiotherapy techniques in this period evolved from 3D-conformal to IMRT and VMAT. In 23 patients electron beams were used. Median age was 63 years (range 41-88), the majority of patients were female (60%). Twenty three patients were > 75 years old. The TNM stages were I, II, IIIA, and IIIB in 18%, 40%, 15% and 27%, 58% of patients had N0 status. Concurrent mitomycin C and 5-fluoruracil-based chemotherapy was given in 63 patients (64%). Five-year overall survival (OS), disease free survival (DFS), locoregional control (LRC) and colostomy free survival (CFS) were 71%, 80%, 82%, and 82% for the whole group. Results in patients > 75 years of age were not statistically different from those in younger patients. With the introduction of more conformal techniques DFS did not change and toxicities decreased. Real word treatment outcomes per disease stage were in line with what is reported in literature. Older patients should also be offered treatment with curative intent. © 2022. The Author(s).

Citation

Karen J Neelis, Django M Kip, Frank M Speetjens, Yvette M van der Linden. Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis. Radiation oncology (London, England). 2022 Apr 20;17(1):81